Celyad Oncology SA

OTCPK:CLYY.F Stock Report

Market Cap: US$15.1m

Celyad Oncology Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenure9.3yrs

Recent management updates

Recent updates

CEO

Celyad Oncology has no CEO, or we have no data on them.

Board Members

NamePositionTenureCompensationOwnership
Michel E. Lussier
Co-Founder & Non-Executive Director19.3yrs€311.000.35%
$ 52.7k
Hilde Windels
Independent Chairwoman of the Board9.3yrs€40.31kno data
Serge Goblet
Non-Executive Director18.3yrs€311.000.13%
$ 18.9k
Margo Roberts
Member of Scientific Advisory Boardno data€10.00kno data
Hinrich Abken
Member of Scientific Advisory Board10.1yrsno datano data
Marco Davila
Member of Scientific Advisory Board10.1yrsno datano data
Marina Blagovic
Independent Director6yrs€40.00kno data
Dominic Piscitelli
Independent Director6yrs€40.00kno data
Ami Shah
Non-Executive Director4.4yrsno datano data
Ann Ager
Member of Scientific Advisory Boardno datano datano data
Christopher LiPuma
Non-Executive Director4.3yrsno datano data
Jean-Christophe Marine
Member of Scientific Advisory Boardno datano datano data
9.3yrs
Average Tenure
67yo
Average Age

Experienced Board: CLYY.F's board of directors are considered experienced (9.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/24 00:38
End of Day Share Price 2026/04/23 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Celyad Oncology SA is covered by 14 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John SavinEdison Investment Research
Edward WhiteH.C. Wainwright & Co.
Guy SipsKBC Securities NV